苏黄止咳胶囊中Vicenin-2经LRP1抑制线粒体自噬依赖性铁死亡治疗感染后咳嗽
本研究探讨苏黄止咳胶囊成分Vicenin-2对感染后咳嗽(PIC)的疗效及机制。采用LPS联合香烟烟雾暴露的ICR小鼠模型和CSE诱导的BEAS-2B细胞模型,发现Vicenin-2改善肺部炎症、氧化应激和气道重塑,抑制线粒体自噬依赖性铁死亡,并通过影响LRP1-Parkin相互作用上调LRP1发挥上述作用。
要点
- Vicenin-2是苏黄止咳胶囊抗PIC的活性成分之一。
- Vicenin-2通过上调LRP1抑制线粒体自噬依赖性铁死亡。
- LRP1缺陷可导致铁死亡,为首次发现。
核心结论
- Vicenin-2通过LRP1抑制线粒体自噬依赖性铁死亡,从而治疗感染后咳嗽,是苏黄止咳胶囊的抗咳嗽成分之一。
研究设计与样本
- 体内建立LPS诱导联合香烟烟雾暴露的ICR小鼠PIC模型,体外用香烟烟雾提取物诱导BEAS-2B细胞。
主要发现
- Vicenin-2显著改善PIC小鼠肺部炎症、氧化应激和气道重塑。
- Vicenin-2抑制线粒体自噬依赖性铁死亡。
- Vicenin-2通过影响LRP1-Parkin相互作用上调LRP1。
- 敲低LRP1可逆转Vicenin-2的体内外药理活性。
- LRP1缺陷导致铁死亡。
临床怎么用
- Vicenin-2可作为苏黄止咳胶囊治疗PIC的质控或活性成分参考。
- 靶向LRP1-Parkin相互作用可能为PIC治疗提供新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Suhuang antitussive capsule (SH) is the only clinically approved traditional Chinese patent medicine for the treatment of post-infectious cough (PIC). During the past decade, our lab has conducted intensive researches on SH, including its efficacy and mechanism on PIC, and determined that SH has favorable anti-inflammatory, antitussive, expectorant, and anti-asthmatic pharmacological effects. Recently, we found that vicenin-2 (VIC-2) could be detected in SH and showed activity in vitro primary screening on PIC. AIM OF THE STUDY: To investigate the therapeutic effects of VIC-2 on PIC and its potential mechanisms, and want to elucidate VIC-2 as one of the efficacious components of SH. MATERIALS AND METHODS: The PIC mouse model was established with lipopolysaccharide (LPS)-induced combined cigarette smoke (CS)-exposed ICR mice, while the in vitro assay was constructed to induce BEAS-2B cells with cigarette smoke extract (CSE). The therapeutic effects of VIC-2 on PIC in vitro and in vivo were assessed by pathological sections, cough assay, immune cell counting, and quantitative-polymerase chain reaction (Q-PCR). The mechanisms of VIC-2 on ferroptosis and mitophagy in PIC were further explored by cell viability assay, Prussian blue staining, lipid peroxidation assessment, confocal laser scanning microscopy, and western blotting. Subsequently, virtual docking, cellular thermal shift assay (CETSA), and drug affinity responsive target stability (DARTS) verified the target relationship between VIC-2 and LDL receptor-related protein 1 (LRP1). In addition, the link between LRP1 and mitophagy-dependent ferroptosis was explored by knocking down LRP1. RESULTS: VIC-2 significantly improved lung inflammation, oxidative stress, and airway remodeling in PIC and inhibited mitophagy-dependent ferroptosis, confirming that it is one of the antitussive components of SH for the treatment of PIC. LRP1 is one of the pharmacological targets of VIC-2, in which VIC-2 exerted the above effects through up-regulating LRP1 by influencing the LRP1-Parkin interaction. The blockade of LRP1 reversed the both in vitro and in vivo pharmacological activities of VIC-2. Furthermore, our results showed for the first time that defects in LRP1 lead to ferroptosis. CONCLUSION: This study demonstrates that VIC-2 inhibits mitophagy-dependent ferroptosis via LRP1 for the treatment of PIC, constituting one of the antitussive components of SH.
引用
- Tian Q, Jiang H, Luan Y, et al. Vicenin-2 in Suhuang antitussive capsule attenuates mitophagy-dependent ferroptosis via LRP1 for treating post-infectious cough. J Ethnopharmacol. 2025. PMID: 40288661. doi:10.1016/j.jep.2025.119880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。